For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Sun Life Financial Inc. (SLF) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score +33 (−100…+100 Quality+Value blend) · Quality 46 · Value 22 · Sentiment 0 (timing only, not weighted) · Composite fair value $100.51 vs $78.26 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Sun Life Financial Inc.
SLF NYSESun Life Financial Inc. is a leading international financial services organization known primarily for its array of insurance and asset management solutions. This Canadian company offers a spectrum of services including life insurance, health insurance, and wealth management to individuals and corporate clients. With deep roots established since 1865, Sun Life operates across North America, Asia, and other global markets, delivering financial security to millions of clients. The firm is recognized for its commitment to sustainable investing and providing clients with the tools to ensure a secure financial future. Sun Life's operations impact key sectors such as healthcare and financial planning, integrating cutting-edge digital innovations to enhance client experience and streamline service delivery. In the broader financial landscape, Sun Life Financial plays a significant role as a trusted provider of risk management tools and investment vehicles, fostering financial well-being and aiding in wealth accumulation.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
This company does not file structured financial statements with the U.S. SEC, so quarterly figures aren't available from our filings-based data engine. Annual figures shown here come from the sources that do cover it.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 4.43
Total Equity: $18.50B
Shares: 608,943,089
Total Debt: $0.00
Cash: $6.97B
EBITDA: N/A
Total Debt: $0.00
Cash: $6.97B
Revenue: $30.21B
Revenue: $30.21B
Revenue: $30.21B
Total Equity: $18.50B
Tax Rate: 21.2%
Equity: $18.50B
Total Debt: $0.00
Cash: $6.97B
Current Liabilities: N/A
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $18.50B
Shares: 608,943,089
Shares: 608,943,089
CapEx: -$105.22M
Shares: 608,943,089
Stock Price: $78.26
Net Income: $2.56B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 19, 2026 11:31am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $25.7B | $16.8B | $29.5B | $28.0B | $30.2B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $6.2B | $6.5B | $7.8B | $8.7B | $9.2B |
| Operating Income | — | — | — | — | — |
| Net Income | $2.9B | $2.3B | $2.3B | $2.3B | $2.6B |
| EBITDA | — | — | — | — | — |
| EPS | $4.85 | $3.76 | $3.80 | $3.80 | $4.45 |
| EPS (Diluted) | $4.82 | $3.76 | $3.79 | $3.79 | $4.43 |
Balance Sheet (Annual)
Last updated: Aug 20, 2026 8:08pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $5.6B | $6.8B | $8.1B | $7.2B | $7.0B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $250.6B | $240.1B | $241.8B | $269.0B | $289.1B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $230.3B | $218.8B | $224.3B | $250.1B | $270.6B |
| Total Equity | $20.4B | $21.3B | $17.6B | $19.0B | $18.5B |
| Retained Earnings | — | — | — | — | — |
Cash Flow (Annual)
Last updated: Aug 20, 2026 8:08pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3B | $3.1B | $4.1B | $1.8B | $2.0B |
| Capital Expenditure | -$58.8M | — | -$124.8M | -$103.8M | -$105.2M |
| Free Cash Flow | -$1.4B | — | $3.9B | $1.7B | $1.9B |
| Acquisitions (net) | -$299.0M | -$1.9B | -$318.6M | $0 | $18.1M |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | -$1.0B | -$1.2B | -$1.4B | -$1.4B | -$1.5B |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | -$2.1B | $1.2B | $1.3B | -$882.4M | -$257.6M |
Growth Trends (YoY %)
Last updated: Aug 19, 2026 11:31am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -34.7% | +75.6% | -5.2% | +8.0% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -22.4% | +1.1% | -1.1% | +13.5% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Aug 19, 2026 11:34am (4d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-27 | $0.70 | — | — | — |
| 2026-02-25 | $0.67 | — | — | — |
| 2025-05-28 | $0.64 | — | — | — |
| 2025-02-26 | $0.59 | — | — | — |
| 2024-11-27 | $0.60 | — | — | — |
| 2024-08-28 | $0.60 | — | — | — |
| 2024-05-29 | $0.59 | — | — | — |
| 2024-02-27 | $0.58 | — | — | — |
| 2023-11-28 | $0.57 | — | — | — |
| 2023-08-29 | $0.55 | — | — | — |
| 2023-05-30 | $0.55 | — | — | — |
| 2023-02-28 | $0.53 | — | — | — |
| 2022-11-22 | $0.54 | — | — | — |
| 2022-08-23 | $0.53 | — | — | — |
| 2022-05-31 | $0.54 | — | — | — |
| 2022-03-01 | $0.52 | — | — | — |
| 2021-11-23 | $0.52 | — | — | — |
| 2021-08-24 | $0.43 | — | — | — |
| 2021-05-25 | $0.45 | — | — | — |
| 2021-02-26 | $0.44 | — | — | — |
Deep Analysis
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-20 23:08The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Starting from the raw tape: Sun Life's five-year revenue line is $25.7B → $16.8B → $29.5B → $28.0B → $30.2B — the 2022 "collapse" is an IFRS 17 accounting artifact, not a business event, so the 1.2% revenue CAGR the momentum module reports is essentially noise. What matters is net income: $2.91B (2021) → $2.26B → $2.28B → $2.26B → $2.56B. That's a business that earned more in 2021 than it did in 2025, with a bump in the most recent year. ROE at 13.97% is respectable but below the ~15%+ the market rewards for insurance compounders (MFC prints similar, IFC does better). ROA at 0.89% is normal for a life insurer but reminds you leverage is doing the work. Operating cash flow of $2.03B against $2.56B net income is a 79% cash conversion — fine for insurance where reserve movements distort OCF, but the -30.2% FCF CAGR the model flags deserves an eye-roll: insurance FCF is a nearly meaningless metric because "capex" isn't the reinvestment channel; reserve build and capital deployment are.
On the prior models: the synthesis pointing to $100.51 fair value / +30% upside is the number I most distrust here. A DCF on an insurer is a hall of mirrors — you're discounting book-value accretion plus dividends, and small changes in the terminal ROE-vs-cost-of-equity spread swing fair value by 40%. At 2.6x book with a 14% ROE and ~10% cost of equity, the Gordon-style fair P/B is roughly (ROE-g)/(COE-g) = (14-4)/(10-4) ≈ 1.67x, which on $18.5B equity and 557M shares implies ~$55/share, not $100. You can flex assumptions to get to $100 (lower COE, higher sustainable ROE, credit for SLC Management's fee streams) but the composite is quietly loading the dice. Meanwhile Market Forces flagging "collapsing cash flows" is misreading insurance accounting. The Narrative layer is the most honest read: boring, durable, fairly priced — no cult, no story premium, no story discount.
The contrarian case worth taking seriously isn't that SLF is a value trap — it's that it's simply fully priced. 17.6x earnings for a company growing EPS at ~6% with a 3.3% yield gets you to a ~9-10% total return, which is fine but not a bargain. The Asian franchise (Hong Kong, Vietnam, India via Aditya Birla) is the only piece with double-digit growth optionality, and it's ~20% of underlying earnings — not enough to re-rate the multiple absent a breakout print. Rate sensitivity cuts both ways: the 2022-2024 rate rise should have juiced net investment income by now, and if $2.56B is what peak-rate earnings look like, the normalized number in a cutting cycle is lower, not higher. Insider activity isn't shown, but Canadian lifecos rarely see meaningful insider buying — absence of signal, not bearish signal. The 57.9% payout ratio leaves room for dividend growth but constrains buyback pace.
I dissent from the synthesis's +30% upside and side closer to the Narrative layer's "fairly valued" framing, but with a downward tilt. My read: fair value sits in the $75-85 band anchored on 1.9-2.2x book and 16-18x earnings, which puts current $78.26 essentially at midpoint. The bull case to $95+ requires either Asian earnings compounding to 30% of the mix or a sustained 15%+ ROE — neither visible in the trailing five-year print where net income is flat. The bear case to $60 requires a credit cycle or reserve charge, which isn't in the data but is the tail risk insurance always carries. For a dividend-growth sleeve, holding is defensible; for new capital seeking 30% upside, the composite is selling a number it can't defend. The stock is a hold, not a buy, and the models are anchoring on a DCF output that doesn't survive contact with insurance-specific valuation math.
GPT Reading
What stands out first is that Sun Life is being valued more like a quality compounder than a plain-vanilla insurer, and the underlying numbers only partly earn that premium. At $78.26, the stock sits on a $43.57B market cap against 2025 net income of $2.56B, or 17.6x earnings, and 2.6x book on $18.50B of equity. For an insurer generating 13.97% ROE and 8.47% net margin, that is not cheap. Yes, earnings have held up well: net income has been remarkably resilient at $2.26B in 2022, $2.28B in 2023, $2.26B in 2024, and then up to $2.56B in 2025, while revenue rose from $27.98B to $30.21B in the latest year. But the five-year picture is less impressive than the recent headline suggests. Revenue is all over the place — $25.73B in 2021, down to $16.82B in 2022, back to $29.52B in 2023, then $27.98B and $30.21B — which tells you insurance accounting noise and market sensitivity are still significant. If the business were truly delivering clean, durable compounding, I would expect either a higher ROE or a lower valuation hurdle.
The second issue is cash generation relative to accounting earnings. Free cash flow of $1.93B against $2.56B of net income is not alarming in absolute terms, but it is notably below earnings and well below where a “fortress” financial should look if the market is paying nearly 18x earnings and 1.6x sales. The momentum summary flags a -30.2% FCF CAGR, and even allowing for the ugliness of insurer cash-flow statements, that deterioration matters because buybacks, dividend growth, and reserve flexibility ultimately lean on distributable cash, not just reported NI. The company does have $6.97B of cash and the debt field here shows zero, which almost certainly reflects data limitations more than literal absence of financial obligations, so I would not over-credit the balance sheet from that line item. What I do credit is consistency: payout ratio at 57.9% and dividend yield at 3.31% look sustainable, but not so compelling that they justify paying a premium multiple for a mid-single-digit earnings grower.
The cleanest way to frame the stock is this: Sun Life looks like a solid business, but the stock already reflects that solidity. A $43.57B equity value against $18.50B of book means the market is capitalizing the franchise at roughly $25B above accounting net worth. To support 2.6x book in insurance, I want confidence that ROE can sustainably sit well above the mid-teens or that growth can accelerate meaningfully. Instead, the data say revenue CAGR of 1.2% and earnings CAGR of 5.9% over the measured period. That is respectable, but not enough for me to embrace a “30% upside” fair-value claim. If I crudely anchor on a more ordinary 1.8x-2.1x book for a quality but not exceptional insurer, fair equity value lands closer to roughly $33B-$39B, implying a share price more like the low $60s to around $70 than $78. Even on earnings, a 13x-15x multiple on $2.56B of earnings gives a market cap of about $33B-$38B, again pointing below the current quote.
The best argument against my caution is straightforward: Sun Life may deserve a premium because the earnings stream has proven much steadier than the revenue line, and the latest year actually shows both growth and quality. Net income rose 13.5% year over year to $2.56B, revenue grew 8% to $30.21B, ROE is a healthy 14%, and the dividend is covered with room to grow. If you believe the market is looking through accounting volatility in reported revenue and rewarding a genuinely diversified platform spanning insurance plus wealth/asset management, then 17.6x earnings is not outrageous. On that view, the 2021-2025 income line demonstrates resilience through different rate and market environments, and the model-based fair value near $100 is simply saying the stock deserves to trade more like a stable financial compounder than a cyclical insurer. I think that case is credible, but I weigh it less heavily because the data here do not show enough growth or enough excess return on equity to clearly justify 2.6x book.
What would change my mind is evidence that Sun Life can turn its accounting stability into unmistakable economic compounding. I would get more constructive if the next year showed net income above $2.8B, ROE moving sustainably above 15%-16%, and free cash flow recovering toward or above net income rather than lagging it. I would also revisit the multiple if book value growth accelerates while the payout ratio stays near 60%, because then 2.6x book starts to look earned rather than assumed. Conversely, if earnings slip back toward the $2.2B-$2.3B range or cash generation weakens again, the current valuation will look plainly too full.
Grok Reading
Sun Life’s numbers describe a mature insurer that is earning its cost of capital cleanly but not compounding in a way that justifies either a growth multiple or the full DCF upside the models are printing. Net income has held a remarkably tight band—$2.26B in 2022, $2.28B in 2023, $2.26B in 2024, then $2.56B in 2025—while reported revenue swung from $16.8B to $30.2B over the same stretch, classic insurance mark-to-market noise rather than operating volatility. The 2025 print delivers an 8.5% net margin, 14.0% ROE, and $1.93B of free cash flow against only $105M of capex, so the franchise is still converting earnings into cash at a high rate in the latest year. Trailing PE of 17.6x and 2.6x book with a 3.3% dividend (58% payout) sit at the expensive end of the historical life-insurance range, yet recent earnings growth of 13.5% year-over-year and an 8% revenue lift show the wealth-management and Asia pieces are finally moving the needle after years of 1.2% revenue CAGR. The balance sheet is unlevered on a debt-to-equity basis and carries $7.0B of cash against $18.5B of equity, which supports the dividend and leaves room for buybacks or bolt-on deals.
What the market is correctly discounting is the multi-year free-cash-flow collapse: FCF CAGR of –30% is not a rounding error, and operating cash flow of $2.03B in 2025, while still solid relative to net income, implies the prior years were materially stronger. That trajectory, paired with ROA of only 0.9%, is exactly the “purchased growth” pattern the market-forces layer flags—top-line and earnings gains that have not yet translated into durable cash generation. At 17.6x earnings a low-growth insurer is fully valued unless the earnings CAGR re-accelerates sustainably above mid-single digits; the composite fair-value print near $101 therefore looks optimistic relative to the cash-flow path and should be treated as an upper bound, not a base case. A more grounded intrinsic range sits closer to the mid-to-high $80s, implying roughly 10–15% upside from $78.26 plus the 3.3% yield—attractive enough to be undervalued, not a 30% gift.
The strongest contrary case is straightforward: PE and PB already embed a quality premium versus global life peers, FCF has been in structural decline, and any reversion in investment markets or tightening of Canadian/Asian regulatory capital could compress both earnings and the multiple simultaneously. A skeptic would also note that 2021 peak earnings of $2.91B have still not been durably reclaimed on a run-rate basis and that the 5.9% earnings CAGR is flattered by the 2022 revenue trough. I weigh those points as real risks but secondary to the latest-year cash conversion, the covered dividend, and the absence of leverage; they cap conviction rather than flip the sign.
I would reverse to fairly valued or overvalued if next two reported periods show FCF remaining below $1.5B or earnings growth falling back under 5% while the multiple holds above 17x; confirmation of sustained FCF above $2.2B and ROE holding 14%+ would push me to higher conviction undervalued.
Big-3 Panel — where each AI stands
Claude — Second Response · fairly valued revised
VERDICT: Fairly valued at $78, tightened range $72-82 (down from $75-85) — GPT's book-multiple discipline moved the midpoint; hold for the 3.3% yield, don't add new capital above $75.
GPT's argument is the one I actually engaged with because it does the same insurance-specific valuation math I did and lands south of me, not north. His 1.8-2.1x book anchor lands at $60-70; my 1.9-2.2x lands at $75-85. The gap is entirely whether you credit SLC Management's fee streams and the Asian growth mix with a premium to a vanilla lifeco book multiple. I do — asset management earnings deserve 12-15x, not 1.8x book — and I'll defend that. But his point that 2.6x book requires sustained ROE well above mid-teens is fair, and my own Gordon math printed $55, which I waved away by saying "flex assumptions." That deserves less waving. If I'm honest, my $75-85 range leans on the higher end of defensible multiples, and GPT's low-$70s anchor is not unreasonable — it's the same math with less generous inputs.
Grok's read moved me less. He calls the stock "modestly undervalued" while simultaneously conceding FCF is in structural decline, ROA is 0.9%, and 17.6x is fully valued absent re-acceleration — then bridges to 10-15% upside via a mid-to-high-$80s intrinsic value he doesn't derive. That's the same hall-of-mirrors problem I flagged in the composite, just with a smaller number. His FCF-decay concern is legitimate but he then underweights it in his own verdict. I take the risk framing, not the price target.
Net: I hold the fairly-valued call but tighten the range downward. GPT's discipline on "what does 2.6x book actually require" pulled my midpoint from ~$80 toward ~$76-78, essentially where the stock trades. I'm not flipping to overvalued because the SLC/Asia mix genuinely earns some premium over pure-play lifecos, but I'm no longer comfortable with the $85 top of my prior band without evidence of 15%+ ROE. The stock is a hold for yield; new capital has better risk/reward waiting for sub-$72.
GPT — Second Response · fairly valued changed direction
VERDICT: Fairly valued around $75-$85, with $78 near the middle; solid dividend grower, but not enough growth or excess ROE to justify a strong upside case above the mid-$80s.
Claude’s pushback moved me more than Grok’s optimism, mainly because he attacked the two weakest links in my first pass with insurer-specific framing. I agree I overweighted reported revenue volatility and especially free-cash-flow decay; for lifecos, IFRS presentation and reserve movements make both far noisier than for an industrial, so the “collapsing FCF” line should not carry the same valuation penalty I gave it. That makes my original low-$60s to $70 anchor too harsh. Just as important, Claude’s point that 2021 net income of $2.91B still exceeds 2025’s $2.56B is a clean rebuttal to any easy “compounder” narrative: the business is durable, but the earnings base is more flat-to-modestly-growing than truly compounding. That keeps me from following Grok to an undervalued call.
What failed to move me is the leap from “latest-year cash conversion is acceptable” and “balance sheet shows no debt” to a 10-15% upside case. The debt datum is almost certainly incomplete for an insurer, so I still won’t underwrite value off that field, and 17.6x earnings plus 2.6x book remains a full multiple for ~14% ROE. Grok is right that $101 is too aggressive and that the latest year was better, but I don’t think one improved print over a five-year flat earnings pattern earns even a mid/high-$80s fair value with much confidence. Claude’s Gordon-style P/B math may be somewhat too punitive if fee-income/Asia deserve franchise credit, yet his broader conclusion survives: this is a quality, income-oriented hold whose current price already reflects most of that quality. So I revise only in degree: less negative on the cash-flow critique, but still not seeing a bargain.
Grok — Second Response · fairly valued changed direction
VERDICT: Fairly valued at $78 — realistic band $75–85 on 2.0–2.2× book / 16–18×; hold for 3.3% yield, not re-rating
Claude’s insurance-specific critique is the piece I underweighted. Treating the –30% FCF CAGR as a core red flag was a category error: for a life insurer, “capex” is not the reinvestment engine and OCF/FCF are distorted by reserve and mark-to-market movements. Once that is set aside, the clean signal is the remarkably stable net-income band plus the 2025 step-up to $2.56 B, 14 % ROE and 79 % cash conversion—respectable, not exceptional. Claude’s Gordon P/B check ((14-4)/(10-4) ≈ 1.67×) also lands harder than I first allowed; even flexing g and COE modestly still leaves 2.6× book looking full rather than cheap. GPT’s 13–15× earnings / 1.8–2.1× book anchors pull in the same direction and correctly flag that the market is already paying a quality premium the mid-single-digit growth record only partly earns.
Those two arguments move me off “modestly undervalued.” My original mid-to-high $80s target implied 10–15 % upside that rested too heavily on giving the latest-year print full credit while downplaying the multiple already embedded. A tighter, insurance-appropriate range is now $75–85, centered on 2.0–2.2× book and 16–18× earnings—exactly where the stock sits. The 3.3 % covered yield and absence of balance-sheet stress still make it a rational hold inside a dividend-growth sleeve, but they do not create a margin of safety large enough to call the shares undervalued. GPT’s sub-$70 bear case over-corrects; the earnings resilience through rate and market cycles justifies staying inside the current band rather than demanding a deep discount.
I therefore revise from modestly undervalued to fairly valued. Confirmation of sustained ROE >15 % or Asia rising cleanly above 25 % of earnings would reopen upside; a slip back to the $2.2–2.3 B income range while the multiple holds would flip me outright cautious.
Advanced Analysis Forensic deep-dive · separate lenses
Sun Life presents as a classic mature earner: revenue of $30.2B in the latest year (up from $25.7B in 2021 with lumpiness typical of insurance accounting), net income steady in the $2.26B-$2.91B band, and FCF of $1.93B most recently. Liquid cash of $6.97B against zero net debt and 16% cash/market-cap gives it a genuinely fortress liquidity posture. Diluted share count has trended down at roughly -1.7% CAGR (653M in 2021 to 439M in 2024, with a rebound to 609M in 2025 that warrants inspection but net direction is favorable), showing management is a net buyer and concentrating per-share value. Earnings quality is the soft spot: OCF/NI at 0.86x means cash conversion trails reported earnings modestly, and accruals at 0.2% of assets are benign but not pristine. The Altman Z of 0.2 flagged as 'distress' is almost certainly a model artifact - Altman Z is calibrated for industrial/manufacturing balance sheets and is notoriously unreliable for insurers whose liability structures (policy reserves) look like distress on that formula. I would not weight it as a genuine survival signal given the $6.97B cash cushion and consistent profitability. Overall this reads as a durable diversified insurer with predictable earnings, disciplined capital return, and no obvious integrity red flags - solidly healthy but not elite, with the wobble in the share count print and the OCF/NI gap keeping it from the top tier.
Verify before trusting this (5)
- Reconcile the diluted share count reported as 439M in 2024 vs 609M in 2025 - likely a data artifact but confirm from proxy/10-K equivalent
- Insurance-specific solvency ratios (LICAT/MCCSR) to override the misleading Altman Z signal
- Segment mix (Canada, US MFS asset management, Asia) and any customer/geographic concentration
- Nature of the OCF/NI gap - underwriting reserves timing vs true accrual quality
- Actual buyback dollars vs SBC issuance to confirm net capital return per share
The e2e composite fair value of $100.51 and signal-adjusted $101.82 imply roughly 28-30% upside from $78.26. Anchored-PE lands at the same $100.51, so the methods agree - this isn't a runaway DCF artifact. For a mature diversified insurer earning consistently, holding a fortress liquidity cushion, and shrinking its share count, a mid-$90s to low-$100s deserved value is defensible on normalized earnings and a mid-teens multiple. That points to a genuine but modest gap, not a dislocation. Against that, the earnings-quality haircut is real: OCF/NI under 1.0 and a messy share-count print argue for trimming deserved value by roughly 5-10%, pulling my quality-adjusted deserved value into the low-$90s. Off ~$92 deserved vs $78.26 price, the margin of safety is ~15% - enough to be interesting for patient capital collecting the dividend, not enough to back up the truck. The bear case (rate pressure, slow organic growth, competitive pricing in mature insurance) is legitimate and is part of why the market discount exists; it isn't pure irrationality. Net: modestly cheap, not deeply cheap. A steady-compounder priced a touch below fair, which is a reasonable entry but not an exceptional one.
Verify before trusting this (5)
- Underlying EPS guidance and normalized ROE trajectory in the next earnings release
- Segment detail on Asian and asset-management growth vs mature North American life/health
- OCF vs reported net income reconciliation and any one-time items depressing cash conversion
- Buyback pace and share-count print consistency across filings
- Capital ratios (LICAT) and any commentary on excess capital deployment
Sun Life sits under almost no active narrative pressure right now. The story is a classic steady-compounder archetype with minimal intensity and low cult coefficient - nobody is euphoric, nobody is panicked, and there is no crowded trade to unwind. That is the defining feature: the absence of sentiment force. With a 0.83 beta and defensive insurance profile, the mildly positive market regime (+17, VIX 16, S&P 2% off highs) barely moves the needle here - risk-on tapes reward high-beta story stocks, not diversified insurers. Recent 8% price action versus 1.2% long-term CAGR hints at quiet accumulation, but there is no narrative catalyst behind it. News flow is benign and low-signal (a routine AI-for-advisors press release, third-party split-corp dividend notices that mention the sector, not SLF directly). No analyst target revisions or tone shift is visible in the brief. The net read is a name the market is largely ignoring - which for a defensive compounder is neither tailwind nor headwind, just drift. The biggest asymmetric sentiment risk is the durable-but-boring bear framing (rate pressure on insurance earnings, mature-market skepticism) reasserting itself if the tape turns risk-off, but at current VIX 16 that pressure is dormant.
Verify before trusting this (4)
- Whether VIX pushes above 20 and forces a defensive rotation that would actually favor SLF's profile
- Any analyst target revisions or rating changes that would inject narrative into a currently story-less name
- Long-end rate direction - a decisive move higher would revive the insurance-tailwind narrative
- Q3 earnings tone and whether management surfaces an AI-productivity or capital-return angle that gives the story some intensity
The world Sun Life operates in is broadly supportive but decelerating. Higher-for-longer rates (10y 4.71%, positive curve) remain a net positive for a life insurer's reinvestment spread and for asset-management fee bases as long as equity markets hold. Structural demographics — retirement decumulation in Canada, protection under-penetration in Asia, employer health cost inflation in the US — are secular volume tailwinds that do not depend on the cycle. Against that, the diversified insurance category is entering a contraction phase: pricing competition in group benefits, softer capital-markets flows, and slowing industry revenue (~2% recent YoY) after a strong three-year run. The net read is a mature compounder whose growth comes from mix, distribution and capital return rather than market expansion — durable mid-single digits, hard to break, hard to inflect.
When we made this prediction on Aug 21, 2026, SLF was $78.80. We expect it to be $88.80 by Feb 2027, and we consider it great value under $70.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 21, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.